Medasense is transforming the way PAIN is being assessed and treated worldwide. Through our breakthrough NOL® AI technology and sensing platform, we quantify pain response to optimize care and avoid overmedication. Medasense’s flagship product, PMD-200™, is used in critical care settings, where patients are unable to communicate, to visualize pain response and personalize treatment. Clinical studies have demonstrated its impact on patient safety and outcomes – including opioid sparing and lower pain scores reported by patients. PMD-200™ is distributed in Europe by Medtronic, and is also commercially available in Canada, Latin America, Israel, Australia and the United Arab Emirates. It enables connectivity with Philips and Mindray patient monitors. Along our path to improve pain care in additional settings, we are harnessing our AI capabilities with NOLedge™, an agile investigational device to lead prediction, stratification and prevention strategies that will enable better pain management and reduce healthcare expenditures.